Shockwave Medical Inc. (SWAV)
(Delayed Data from NSDQ)
$43.43 USD
+2.29 (5.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $43.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.43 USD
+2.29 (5.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $43.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Shockwave Medical (SWAV) Gains 0.6% Post Q3 Earnings Beat
by Zacks Equity Research
Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and expansion in gross margin.
Shockwave Medical (SWAV) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 171.43% and 5.12%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Shockwave Medical (SWAV) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ShockWave Medical (SWAV) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
ShockWave Medical (SWAV) has been struggling lately, but the selling pressure may be coming to an end soon.
Is First Trust Mid Cap Growth AlphaDEX ETF (FNY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FNY
ShockWave Medical (SWAV) Q2 Earnings, Revenues Top Estimates
by Zacks Equity Research
ShockWave Medical's (SWAV) robust performance across product lines and geographies drive its Q2 sales.
Company News for Aug 10, 2021
by Zacks Equity Research
Companies In The News Are: BALY, CRNC, SWAV, VTRS
Shockwave Medical (SWAV) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 97.56% and 28.12%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Why ShockWave Medical (SWAV) Might Surprise This Earnings Season
by Zacks Equity Research
ShockWave Medical (SWAV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Shockwave Medical (SWAV) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Shockwave Medical (SWAV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
Shockwave Medical (SWAV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of -61.90% and 1.44%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stock Q1 Earnings on May 10: MRVI, TGTX & More
by Urmimala Biswas
The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
Shockwave Medical (SWAV) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of -12.20% and 11.60%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Shockwave Medical (SWAV) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shockwave Medical (SWAV) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 30.91% and 34.87%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Shockwave Medical (SWAV) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shockwave Medical (SWAV) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 15.15% and 6.04%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Shockwave Medical (SWAV) Q2 Earnings Expected to Decline
by Zacks Equity Research
Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shockwave Medical (SWAV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of -22.92% and 20.52%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shockwave Medical (SWAV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for DENTSPLY SIRONA (XRAY) in Q3 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) Q3 earnings to reflect better-than-expected performance at Technology & Equipment and growth in emerging markets.
What's in the Cards for Cardinal Health (CAH) in Q1 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) Q1 earnings are likely to reflect better-than-expected performance at Pharmaceutical and Medical segments.
AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) Q4 earnings are likely to reflect the better-than-expected performance at Pharmaceutical Distribution and higher revenues.
DexCom (DXCM) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
DexCom's (DXCM) Q3 earnings is likely to reflect top-line growth and rising global awareness of the company's real-time CGM.